AI Article Synopsis
- The study focuses on (NaYF:Yb,Er) microparticles that convert 980 nm infrared light into 540 nm visible light using a two-photon process.
- Mirrors placed around the sample significantly enhance the output light intensity by three times.
- The researchers created microparticle-coated lenses for eyeglasses, allowing users to view intense infrared light images transformed into visible light.
Article Abstract
In this study, (NaYF:Yb,Er) microparticles dispersed in water and ethanol, were used to generate 540 nm visible light from 980 nm infrared light by means of a nonlinear stepwise two-photon process. IR-reflecting mirrors placed on four sides of the cuvette that contained the microparticles increased the intensity of the upconverted 540 nm light by a factor of three. We also designed and constructed microparticle-coated lenses that can be used as eyeglasses, making it possible to see rather intense infrared light images that are converted to visible.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209170 | PMC |
| http://dx.doi.org/10.1038/s41598-023-35164-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bioorthogonal Janus microparticles for photothermal and chemo-therapy.
Smart Med
December 2024
Shanghai Xuhui Central Hospital Zhongshan-Xuhui Hospital, and the Shanghai Key Laboratory of Medical Epigenetics International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology) Institutes of Biomedical Sciences Fudan University Shanghai China.
Bioorthogonal chemistry, recognized as a highly efficient tool in chemical biology, has shown significant value in cancer treatment. The primary objective is to develop efficient delivery strategies to achieve enhanced bioorthogonal drug treatment for tumors. Here, Janus microparticles (JMs) loaded with cyclooctene-modified doxorubicin prodrug (TCO-DOX) and tetrazine-modified indocyanine green (Tz-ICG) triggers are reported.
View Article and Find Full Text PDFRed cell microparticles produced using high-pressure extrusion enhance both primary and secondary hemostasis.
Pharmacol Rep
January 2025
Department of Neurology, Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, 1600 NW 10th Ave RMSB #7046, Miami, FL, 33136, USA.
Background: Current therapies to treat excessive bleeding are associated with significant complications, which may outweigh their benefits. Red blood cell-derived microparticles (RMPs) are a promising hemostatic agent. Previous studies demonstrated that they reduce bleeding in animal models, correct coagulation defects in patient blood, and have an excellent safety profile.
View Article and Find Full Text PDFTumor-Repopulating Cell-Derived Microparticle-Based Therapeutics Amplify the Antitumor Effect through Synergistic Inhibition of Chemoresistance and Immune Evasion.
Mol Pharm
January 2025
National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Traditional chemotherapy often encounters failure attributed to drug resistance mediated by tumor-repopulating cells (TRCs) and chemotherapy-triggered immune suppression. The effective inhibition of TRCs and the mitigation of drug-induced immune suppression are pivotal for the successful chemotherapy. Here, TRC-derived microparticles (3D-MPs), characterized by excellent tumor-targeting and high TRC uptake properties, are utilized to deliver metformin and the chemotherapeutic drug doxorubicin ((DOX+Met)@3D-MPs).
View Article and Find Full Text PDFMicroemulsion-Inspired Polysaccharide Nanoparticles for an Advanced Targeted Thrombolytic Treatment.
ACS Nano
January 2025
UMR-S U1148 INSERM, Laboratory for Vascular Translational Science (LVTS), Université Paris Cité, Université Sorbonne Paris Nord, F-75018 Paris, France.
Among cardiovascular diseases, thrombotic diseases such as ischemic heart disease and acute ischemic strokes are the most lethal, responsible by themselves for a quarter of worldwide deaths. While surgical treatments exist, they may not be used in all situations, and systemic thrombolytic drug injection, such as recombinant tissue plasminogen activators (rtPA), often remains necessary, despite serious limitations including short therapeutic window, severe side effects, and failure to address the complex nature of thrombi. This prompted intense research into alternative thrombolytics or delivery methods, including nanomedicine.
View Article and Find Full Text PDFEffect of Process Parameters on Nano-Microparticle Formation During Supercritical Antisolvent Process Using Mixed Solvent: Application for Enhanced Dissolution and Oral Bioavailability of Telmisartan Through Particle-Size Control Based on Experimental Design.
Pharmaceutics
November 2024
College of Pharmacy and Research Institute for Drug Development, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan 46241, Republic of Korea.
This study investigates the impact of supercritical antisolvent (SAS) process parameters on the particle formation of telmisartan, a poorly water-soluble drug. A fractional factorial design was employed to examine the influence of the SAS process parameters, including solvent ratio, drug solution concentration, temperature, pressure, injection rate of drug solution, and CO₂ flow rate, on particle formation. Solid-state characterizations of the SAS process particles using XRD and FT-IR confirmed their amorphous nature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!